News Archives - Page 208 of 703

MondayNov 07, 2022 10:30 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Is ‘One to Watch’

BiondVax has an exclusive worldwide license to commercialize NanoAbs for the treatment of COVID-19 The company plans to initiate a Phase 1/2a clinical trial of its inhaled COVID-19 therapeutic NanoAb in 2023 BiondVax has exclusive options for worldwide licenses for NanoAbs to treat other disorders with large, underserved needs The company has filed a Registration Statement with the SEC for an underwritten offering of shares BiondVax Pharmaceuticals (NASDAQ: BVXV) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses. In collaboration with the prestigious Max Planck Institute…

MondayNov 07, 2022 9:45 am

New Pharmaceutical Subsidiary Geared to Aid Odyssey Health, Inc. (ODYY) Development of Novel Solutions for Brain Related Medical Treatments

Odyssey Health Inc. is a medical product developer with a mission of filling unmet needs when it comes to acute emergencies involving patients’ central nervous systems The company recently announced the formation of a wholly owned subsidiary to help Odyssey develop its products as they move through the regulatory process Odyssey’s solutions include a breath-powered intranasal delivery mechanism and synthetic neurosteroids designed to provide rapid-response treatment for patients with concussions and a highly fatal pediatric neurological disease Odyssey Health also is developing solutions for heart disease detection, obstructed-airway choking and nerve agent exposure The concussion therapeutic solution recently completed Phase…

MondayNov 07, 2022 9:00 am

Flora Growth Corp. (NASDAQ: FLGC) Agreement to Acquire Multi-national Cannabis Operator Positions Company for New Strategic Growth in Europe

Flora Growth is a cannabis cultivator and international brand developer with a strong base of operations at its licensed facility in northern Colombia Flora recently announced its plans to acquire multi-national operator Franchise Global Health (“FGH”), the latest of its strategic acquisitions designed to boost revenues and expand Flora’s international footprint FGH is focused on the German market, where its subsidiary was the first company to sell cannabis Germany is in turn expected to provide the companies a launching pad for success in Europe, where opportunity is defined by the fact that currently Germany provides 75 to 80 percent of…

FridayNov 04, 2022 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Zero Adverse Effects from Successful HYPER-H21-4 Study of DehydraTECH(TM)-CBD for High Blood Pressure

The CDC reported more than 670,000 annual deaths in the United States with high blood pressure as a primary or contributing cause Lexaria's patented DehydraTECH(TM) technology has been shown, through HYPER-H21-4 study, to decrease high blood pressure in subjects through DehydraTECH-CBD-enabled dosing The global antihypertension drug market was valued at over $22.5 billion in revenue in 2018 and is expected to grow at a CAGR of 3.1%, resulting in a market of over $28.7 billion by 2026 In the United States, uncontrolled high blood pressure is common among adults – with only one in four having the condition under control.…

FridayNov 04, 2022 9:45 am

Silo Pharma Inc. (NASDAQ: SILO) Extends Columbia University Agreement to Continue Research for Therapeutics to Treat Alzheimer’s Disease

Silo recently extended Columbia University agreement to continue research for novel therapeutics to treat Alzheimer’s disease and stress-induced anxiety disorder Preclinical studies demonstrate Silo’s jointly-developed Z-pod(TM) delivery technology holds and distributes therapeutics in a time-released manner to potentially provide targeted delivery Additional treatment research includes funding for the UCSF Translational Psychedelic Program to study effects of psilocybin on various inflammatory conditions Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company, fuses traditional therapeutics with psychedelic medicine to treat numerous underserved conditions, including fibromyalgia, post-traumatic stress disorder, and Alzheimer’s disease. Through a joint partnership agreement with Columbia University, researchers are currently…

ThursdayNov 03, 2022 10:30 am

Tampa Alternative Products Expo Brings Together The Local Community For Three Days of Festivity And Business Networking

After various successful shows across North and South America, Alternative Products Expo is coming to Tampa, Florida, this November 10-10, at Tampa's Convention Center. The event has something for everyone. It features over 250 industry vendors, 20+ speakers from across the industry, and many contests and giveaways. Starting some years ago with a series of successful Vape events, the Alt Pro Expo team ventured into organizing events for the alternative products sector. These products have significantly disrupted traditional markets, offering people different choices regarding entertainment and health. Among these categories, attendees can find options like kratom, dietary supplements, hemp derivatives,…

ThursdayNov 03, 2022 9:00 am

Cannabis Regulation in the Spotlight During Midterm Elections at the Heels of Presidential Pardon; Flora Growth Corp. (NASDAQ: FLGC) Leveraging Colombian Stance to Manufacture Products at Lower Costs

President Biden issued a pardon for federally incarcerated inmates with minor marijuana possession charges, urging governors to do the same at the state level The President also requested a reclassification of cannabis, as it is currently listed above other drugs which are key factors in the overdose epidemic Flora Growth, through its Colombian cultivation, is producing a higher quality product at lower-than-average cost margins due to the country's stance on cannabis regulations With midterm elections right around the corner, voters in five states – Arkansas, Maryland, Missouri, North Dakota, and South Dakota - will determine the legality of recreational marijuana…

WednesdayNov 02, 2022 10:30 am

DGE’S 3rd Human Factors Engineering Usability Studies Congress to Unite Leaders for Discussions on Usability Testing Challenges

Medical experts from all over the globe are invited to attend the 3rd Human Factors Engineering & Usability Studies Congress, a live-streaming event that will help medical device professionals adapt to regulatory challenges, logistics, and scheduling issues in a remote work environment. The event is hosted by Dynamic Global Events (“DGE”), a Life Science leader in organizing b2b events. The global event company caters to the informational and networking needs of the Pharmaceutical, Biotechnology, Healthcare, Medical Devices, and allied industries. The conference will commence with an opening speech from Joseph Purpura, Associate VP, Executive Director, and Head of Medical Device Safety, ABBVIE…

WednesdayNov 02, 2022 9:45 am

India Globalization Capital Inc. (NYSE American: IGC) Is ‘One to Watch’

IGC’s leading drug candidate, IGC-AD1, has completed Phase 1 of a safety and tolerability trial and entered Phase 2 trials for treating agitation in patients with Alzheimer’s dementia As of September 2022, the IGC trial is the only ongoing Phase 2 trial of a natural THC based formulation on Alzheimer’s patients The company’s other drug candidate, TGR-63, is an enzyme inhibitor that has shown in preclinical trials the potential to reduce neurotoxicity in Alzheimer’s cell lines Alzheimer’s disease impacts over 55 million people worldwide and about 5.5 million individuals in the U.S. India Globalization Capital (NYSE American: IGC), through subsidiary…

Site Search

Company Search

Category: News